CHPLAPHARM Arzneimittel GmbH has successfully completed the refinancing of existing loans and promissory notes.
The new credit facilities totalling 780 million euros were closed per 12.07.2018 with Deutsche Bank, HSBC and UniCredit using Capital Markets London. The placement with international investors was additionally supported by Commerzbank, DZ Bank and Santander, as well as GCA Altium, Latham & Watkins and Heuking Kühn Lüer Wojtek.
"Following the successful establishment of a global Partner network, CHEPLAPHARM is now able to continue the long-standing success story due to the new financing structure by further scaling the business model," explained Sebastian F. Braun (CEO) after the negotiations were concluded.
The new credit facilities ensure that the group's long-term financing is flexible and sustainably secured. In addition to the return of existing loans and promissory notes, there is a significant amount of additional liquidity available to finance future M&A projects. The new financing structure offers CHEPLAPHARM a significant increase in flexibility at attractive conditions. The London market for long-term loans (TLB market) also offers the option of flexible increases to support future growth.
Contact Investor Relations:
CHEPLAPHARM Arzneimittel GmbH | Jens Remmers | Ziegelhof 24 | 17489 Greifswald | investor-relations(at)cheplapharm.com